ArticleBreast cancer research and treatment2024

Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.

Faina Nakhlis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.